Related references
Note: Only part of the references are listed.Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Dong Ding et al.
ADVANCES IN THERAPY (2020)
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer (vol 33, pg 853, 2018)
Matthew D. Hellmann et al.
CANCER CELL (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma A Cost-effectiveness Analysis
XiaoMin Wan et al.
JAMA ONCOLOGY (2019)
Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first line treatment of extensive-stage small-cell lung cancer
Kexun Zhou et al.
LUNG CANCER (2019)
First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis
XiaoMin Wan et al.
CANCER (2019)
Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up
Szu-Chun Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
Longjiang She et al.
LUNG CANCER (2019)
Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC)
Shirish M. Gadgeel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US
Ralph P. Insinga et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Current standards for clinical management of small cell lung cancer
Anna F. Farago et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)
L.V. Sequist et al.
ANNALS OF ONCOLOGY (2017)
Health state utilities in non-small cell lung cancer: An international study
Beenish Nafees et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma
Christine G. Kohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States
Min Huang et al.
PHARMACOECONOMICS (2017)
The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK plus ) advanced NSCLC previously treated with crizotinib
J. J. Carlson et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression
Pedro Aguiar et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis
Daniel A. Goldstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States
Jie Ting et al.
VALUE IN HEALTH (2015)
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody
Ross Stewart et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Small Cell Lung Cancer: Where Do We Go From Here?
Lauren Averett Byers et al.
CANCER (2015)
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Frueh et al.
ANNALS OF ONCOLOGY (2013)
Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Antonio Rossi et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Cost Effectiveness of Personalized Therapy for First-Line Treatment of Stage IV and Recurrent Incurable Adenocarcinoma of the Lung
Elizabeth A. Handorf et al.
JOURNAL OF ONCOLOGY PRACTICE (2012)
Cost-Effectiveness of Temsirolimus for First Line Treatment of Advanced Renal Cell Carcinoma
Martin Hoyle et al.
VALUE IN HEALTH (2010)
Health state utilities for non small cell lung cancer
Beenish Nafees et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2008)
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer
John R. Eckardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
